Declines in breast cancer after the WHI: apparent impact of hormone therapy

被引：32

作者：

Clarke, Christina A. ^{[1
]}

Glaser, Sally L.

机构：

[1] No Calif Canc Ctr, Fremont, CA USA

[2] Stanford Comprehens Canc Ctr, Stanford, CA USA

来源：

CANCER CAUSES & CONTROL | 2007年 / 18卷 / 08期

关键词：

breast cancer; incidence time trends; hormone therapy; estrogen/progestin; population attributable fraction;

D O I：

10.1007/s10552-007-9029-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Large numbers of US women stopped taking hormone therapies (HT), especially estrogen/progestin (EP) formulations, after the Women's Health Initiative trial detected elevated risks of breast cancer in EP users and was halted in July 2002. Recent reports have indicated substantial and significant declines in population-based breast cancer incidence, particularly hormone-sensitive forms, for 2003 and 2004. Are these events linked? This commentary considers the available evidence linking the mass cessation of HT in 2002 to the breast cancer incidence declines of 2003/2004 and quantifies the potential impact of the cessation on the overall burden of breast cancer in the US.

引用

页码：847 / 852

页数：6

共 35 条

[1] Prior hormone therapy and breast cancer risk in the Women's Health initiative randomized trial of estrogen plus progestin [J].

Anderson, Garnet L. ;

Chlebowski, Rowan T. ;

Rossouw, Jacques E. ;

Rodabough, Rebecca J. ;

McTiernan, Anne ;

Margolis, Karen L. ;

Aggerwal, Anita ;

Curb, J. David ;

Hendrix, Susan L. ;

Hubbell, F. Allan ;

Khandekar, Jamardan ;

Lane, Dorothy S. ;

Lasser, Norman ;

Lopez, Ana Maria ;

Potter, JoNell ;

Ritenbaugh, Cheryl .

MATURITAS, 2006, 55 (02) :103-115

[2]

[Anonymous], 2006, BEH RISK FACT SURV S

[3]

AUSTIN DF, 1979, J NATL CANCER I, V62, P13

[4] THE DECREASING INCIDENCE OF ENDOMETRIAL CANCER - PUBLIC-HEALTH IMPLICATIONS [J].

AUSTIN, DF ;

ROE, KM .

AMERICAN JOURNAL OF PUBLIC HEALTH, 1982, 72 (01) :65-68

[5]

Beral Valerie, 2003, Lancet, V362, P419, DOI 10.1016/S0140-6736(03)14065-2

[6] THE RISK OF BREAST-CANCER AFTER ESTROGEN AND ESTROGEN PROGESTIN REPLACEMENT [J].

BERGKVIST, L ;

ADAMI, HO ;

PERSSON, I ;

HOOVER, R ;

SCHAIRER, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (05) :293-297

[7]

*CAL HLTH INT SURV, 2007, CHIS PUBL US FIL

[8]

*CDC, 2007, US MAMM AM WOM AG

[9] Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women - The Women's Health Initiative Randomized trial [J].

Chlebowski, RT ;

Hendrix, SL ;

Langer, RD ;

Stefanick, ML ;

Gass, M ;

Lane, D ;

Rodabough, RJ ;

Gilligan, MA ;

Cyr, MG ;

Thomson, CA ;

Khandekar, J ;

Petrovitch, H ;

McTiernan, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (24) :3243-3253

[10] Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors [J].

Clarke, Christina A. ;

Purdie, David M. ;

Glaser, Sally L. .

BMC CANCER, 2006, 6 (1)

← 1 2 3 4 →